Apple cuts first-quarter production plan for new iPhones by 10 percent:...
Apple Inc , which slashed its quarterly sales forecast last week, has reduced planned production for its three new iPhone models by about 10 percent for the January-March quarter, the Nikkei Asian Review reported on Wednesday.
Vanadium drives uranium project developments – World Nuclear News
As vanadium prices increase, uranium miners in the USA and elsewhere are looking to capitalise on the vanadium that is co-present with uranium in certain deposits to add value to their operations.
New York Manufacturing Index Indicates Rebound In Pace Of Growth |...
(RTTNews) - After reporting an unexpected slowdown in the pace of growth in New York manufacturing activity in the previous month, the Federal Reserve Ban
LaSalle to enter U.S. debt market with acquisition –
LaSalle Investment Management, an arm of Jones Lang LaSalle Inc., is betting big on U.S. commercial real estate debt. LaSalle is acquiring a majority stake in Latitude Management Real Estate Invest…
Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global...
Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer hea
U.S. Crude Oil Inventories Fell by 0.5M Barrels Last Week: EIA...
U.S. Crude Oil Inventories Fell by 0.5M Barrels Last Week: EIA
US credit demand declines, rejection rates rise: NY Fed survey
Americans' demand for credit declined over the previous year as expected, as mortgage interest rates rose, while the percentage of approve
Source: www.channelnewsasia.com
U.S. demand for...
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S. | Business Wire
Sun Pharma launches ready-to-infuse INFUGEM - the first and only chemotherapy product in a premixed, ready-to-infuse formulation - in the US.
Oil drillers cut rigs for third week in a row: Baker...
U.S. energy firms this week cut the number of oil rigs operating for a third week in a row to the lowest level in 10 months as independent producers follow through on plans to cut spending even though oil majors plan to spend more.
AveXis Presents Data Showing Efficacy Of Zolgensma In Broad Spectrum Of...
AveXis, a Novartis company, announced interim data from ongoing trials of the investigational product Zolgensma or onasemnogene abeparvovec-xioi; AVXS-101 that showed positive results across a broad spectrum of patients with spinal muscular atrophy or SMA.
